Jacksonville, FL Clinical Trials Report — June 2026

For Jacksonville residents considering participation in clinical research, June 2026 presents a dynamic landscape of opportunities, with some trials requiring prompt action due to impending deadlines.

A total of 58 clinical trials in Jacksonville are scheduled to conclude within the next 90 days. This includes 7 trials that are still actively seeking healthy volunteers, offering a chance to contribute to medical advancements before their enrollment windows close.

New Opportunities for Healthy Volunteers

This month brings promising news for individuals without specific health conditions looking to participate. Of the 17 new trials launched in Jacksonville this June, 3 are accepting healthy volunteers. Overall, there are now 60 trials actively recruiting healthy participants across the city, providing numerous avenues for those interested in supporting medical research.

Leading Research Facilities in Jacksonville

Jacksonville is home to several prominent research institutions that consistently run a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• Mayo Clinic in Florida (159 trials)
• Mayo Clinic (72 trials)
• Mayo Clinic Florida (62 trials)
• Mayo Clinic Jacksonville (44 trials)
• Research Site (41 trials)
• Nemours Children's Clinic-Jacksonville (30 trials)
• Baptist MD Anderson Cancer Center (21 trials)
• Jacksonville Center for Clinical Research (21 trials)
• Mayo Clinic - Jacksonville (13 trials)
• Cancer Specialists of North Florida (13 trials)
• University of Florida (12 trials)
• Baptist Health Research Institute (8 trials)

The Mayo Clinic network, with its various specialized centers, stands out as the most active research hub in the city, offering a broad spectrum of studies.

Notable New Trials Launched in June

Jacksonville saw the opening of 17 new clinical trials this month, an increase from the 14 trials that launched in May 2026. This brings the total number of actively recruiting clinical trials in Jacksonville, FL, to 871 across 300 research facilities. Several high-profile new trials from major sponsors are now recruiting, offering participants the chance to engage with cutting-edge treatments:

• AstraZeneca is sponsoring a significant Phase 3 study, NCT07662213, "A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus." This trial aims for 1,200 participants to evaluate the efficacy, safety, and tolerability of elecoglipron compared with oral semaglutide in adults with Type 2 Diabetes Mellitus and increased cardiovascular risk.
• Another Phase 3 trial from Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics, is NCT07654374, "A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)." This study seeks 1,100 participants to evaluate the long-term efficacy, safety, and tolerability of aleniglipron in individuals living with overweight or obesity and Type 2 Diabetes Mellitus.
• Stryker Orthopaedics is leading the "Mako-MORE Registry," NCT07647354, a prospective, post-market observational study with 950 participants. This registry collects real-world clinical data on patients undergoing joint arthroplasty with Stryker implants, with or without the Mako Robotic-Arm Assisted System.
• The Mayo Clinic is sponsoring NCT07670117, "HAIQU (Hospital AIr QUality)," which aims to assess whether an aerosol biosensor and air quality risk assessment software can improve indoor air quality in hospital environments and reduce respiratory disease risk factors, involving 850 participants.
• Another Phase 3 study from AstraZeneca is NCT07662044, "A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus." This trial plans for 800 participants to evaluate elecoglipron's efficacy and safety in adults with Type 2 Diabetes Mellitus inadequately managed with lifestyle changes or other glucose-lowering medications.
• Novo Nordisk A/S is sponsoring NCT07668414, "A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide." This Phase 3 study aims for 650 participants to determine if zenagamtide is safe and effective for treating excess body weight compared to semaglutide.

New trials this month are exploring a range of conditions, with the most frequent being overweight (2 trials), type 2 diabetes mellitus (2 trials), and obesity (2 trials). Other conditions include arthropathy of knee, back pain, chronic weight management, colorectal carcinoma, depression, depression disorder, and fibromyalgia. Drug trials account for the largest share of new studies, with 11 new drug trials, followed by 3 other types of studies, 2 device trials, 1 diagnostic test, and 1 genetic study.

Trials Nearing Enrollment Deadlines

For patients managing specific health conditions, several trials are closing soon. Conditions with trials nearing their enrollment deadlines include:

• Ischemic stroke (2 trials)
• Intracranial aneurysm (2 trials)
• Major depressive disorder (2 trials)
• Stroke (2 trials)
• Amputees (1 trial)
• Amyotrophic lateral sclerosis (1 trial)
• Adult primary liver cancer (1 trial)
• Atopic dermatitis (1 trial)
• Alzheimer's disease (1 trial)
• Atrial fibrillation (AF) (1 trial)

Who Can Participate?

Participation in clinical trials is open to a diverse range of individuals. Of the 17 new trials launched this month, 14 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Currently, 1 new trial is female-only, while no new trials are male-only or include children.

Industry sponsors are driving a significant portion of new research in Jacksonville, with 11 new trials sponsored by industry. Academic institutions are also active, sponsoring 6 new trials. The Mayo Clinic leads academic sponsorship with 4 new trials, while AstraZeneca leads industry sponsorship with 2 new trials.

Broadening Your Search: Nearby Options

While Jacksonville offers a robust array of clinical trial opportunities, individuals may also find options in nearby communities within Florida. Cities with active trials include Miami (24 trials), Orlando (16 trials), Tampa (13 trials), Maitland (8 trials), Ocala (7 trials), Leesburg (6 trials), Ocoee (5 trials), and Hollywood (5 trials).

As we move through June, Jacksonville's active research community continues to drive medical innovation, offering diverse opportunities for individuals to contribute to the future of healthcare.